|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
1993-8-26
|
|
pubmed:abstractText |
Attempts to increase dose-intensity in clinical practice have been limited by cumulative hematologic toxicity despite the use of hematopoietic growth factors. To address this problem, we designed a study to determine whether four cycles of dose-intensive chemotherapy with carboplatin could be administered in the outpatient setting using granulocyte-macrophage colony-stimulating factor (GM-CSF) and peripheral-blood progenitor cells (PBPCs) that had been harvested before initiation of treatment.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
N
|
|
pubmed:pagination |
1583-91
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:8101563-Adult,
pubmed-meshheading:8101563-Aged,
pubmed-meshheading:8101563-Ambulatory Care,
pubmed-meshheading:8101563-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:8101563-Bone Marrow Diseases,
pubmed-meshheading:8101563-Carboplatin,
pubmed-meshheading:8101563-Cryopreservation,
pubmed-meshheading:8101563-Cyclophosphamide,
pubmed-meshheading:8101563-Female,
pubmed-meshheading:8101563-Granulocyte-Macrophage Colony-Stimulating Factor,
pubmed-meshheading:8101563-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:8101563-Humans,
pubmed-meshheading:8101563-Leukapheresis,
pubmed-meshheading:8101563-Male,
pubmed-meshheading:8101563-Middle Aged,
pubmed-meshheading:8101563-Neoplasms,
pubmed-meshheading:8101563-Ovarian Neoplasms
|
|
pubmed:year |
1993
|
|
pubmed:articleTitle |
Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy.
|
|
pubmed:affiliation |
Department of Medicine, Dana-Farber Cancer Institute, Boston, MA.
|
|
pubmed:publicationType |
Journal Article
|
